Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World REKOVELLE study targets IVF success in asian women

NCT ID NCT06561958

Knowledge-focused Sponsor: Ferring Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 1,500 Asian women using REKOVELLE for the first time during IVF to see how well it works in everyday medical practice. Researchers will track live birth rates and how the drug is used. The goal is to understand its real-world effectiveness and safety for this specific group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REKOVELLE (a hormone drug for ovarian stimulation)
What this could lead to
If successful, this study could confirm that REKOVELLE is effective and safe for Asian women, potentially improving IVF success rates in this population.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment, only gathers real-world data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.

Ages

20 years and older

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females aged 20 years or older at enrollment * Serum AMH level \>0.5 ng / mL (with the latest result tested within 12 months) * Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable) * Willing and able to provide written informed consent Exclusion Criteria: * Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment * Participating in an interventional clinical trial in which any medication treatment is mandated * Women with a contraindication for prescription of REKOVELLE treatment * Oocyte donors * Undergoing ovarian stimulation for fertility preservation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility

Contacts and locations

Locations

  • Ferring Investigational Site

    Chiba, Chiba, 2610023, Japan

  • Ferring Investigational Site

    Fukuoka, Fukuoka, 8120013, Japan

  • Ferring Investigational Site

    Kitakyushu, Fukuoka, 8070825, Japan

  • Ferring Investigational Site

    Takasaki, Gunma, 3700841, Japan

  • Ferring Investigational Site

    Hiroshima, Hiroshima, 7320822, Japan

  • Ferring Investigational Site

    Bunkyō City, Japan, 1130033, Japan

  • Ferring Investigational Site

    Tokyo, Tokyo, 1600023, Japan

  • Ferring Investigational Site

    Hiroshima, 7300035, Japan

  • Ferring Investigational Site

    Hokkaido, 0600003, Japan

  • Ferring Investigational Site

    Hyōgo, 6500021, Japan

  • Ferring Investigational Site

    Osaka, 5300011, Japan

  • Ferring Investigational Site

    Osaka, 5500015, Japan

  • Ferring Investigational Site

    Saitama, 3540035, Japan

  • Ferring Investigational Site

    Busan, Busan, 49241, South Korea

  • Ferring Investigational Site

    Daegu, Daegu, 41910, South Korea

  • Ferring Investigational Site

    Seongnam-si, Seongnam, 13496, South Korea

  • Ferring Investigational Site

    Busan, 47245, South Korea

  • Ferring Investigational Site

    Tainan, Tainan, 70403, Taiwan

  • Ferring Investigational Site

    Tainan, Tainan, 71004, Taiwan

  • Ferring Investigational Site

    Taoyuan, Taoyuan, 333, Taiwan

  • Ferring Investigational Site

    Taichung, 406, Taiwan

  • Ferring Investigational Site

    Taipei, 100225, Taiwan

  • Ferring Investigational Site

    Taipei, 110, Taiwan

  • Ferring Investigational Site

    Bangkok, 10700, Thailand

  • Ferring Investigational Site

    Hanoi, Hanoi, 100000, Vietnam

  • Ferring Investigational Site

    Ho Chi Minh City, Ho Chi Minh City, 700000, Vietnam

  • Ferring Investigational Site

    Ho Chi Minh City, Ho Chi Minh City, Vietnam

  • Ferring Investigational Site

    Huế, Huế, 49000, Vietnam

  • Maria Fertility Hospital

    Seoul, 02586, South Korea

  • Naresuan University Hospital

    Phitsanulok, Muang, 65000, Thailand

  • Ramathibodi Hospital

    Bangkok, Ratchathewi, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.